Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Total Current Liabilities (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Total Current Liabilities for 5 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 67.66% to $6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Dec 2025, down 67.66% year-over-year, with the annual reading at $6.6 million for FY2025, 67.66% down from the prior year.
  • Total Current Liabilities hit $6.6 million in Q4 2025 for Kezar Life Sciences, down from $13.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $20.4 million in Q3 2024 to a low of $5.9 million in Q2 2021.
  • Historically, Total Current Liabilities has averaged $12.6 million across 5 years, with a median of $13.5 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: surged 95.53% in 2023 and later tumbled 67.66% in 2025.
  • Year by year, Total Current Liabilities stood at $8.2 million in 2021, then soared by 33.91% to $11.0 million in 2022, then skyrocketed by 61.35% to $17.7 million in 2023, then rose by 14.57% to $20.3 million in 2024, then crashed by 67.66% to $6.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for KZR at $6.6 million in Q4 2025, $13.4 million in Q3 2025, and $14.4 million in Q2 2025.